Asia’s Startup Funding Surpasses $229 Million, Led by WIRobotics and Scapia

*TL;DR: Asia’s startup ecosystem raised over $229 million this week, driven by mega‑rounds for South Korea’s WIRobotics ($68 M) and India’s Scapia ($63 M).

Context Capital continued to flow into Asian startups across robotics, fintech, biotech and consumer tech. The region posted more than $229 million in new funding, indicating sustained investor appetite for deep‑tech and health‑focused ventures while early‑stage consumer platforms also secured backing.

Key Facts - WIRobotics closed a $68 million Series B round, led by JB Investment. The South Korean firm develops the humanoid platform ALLEX, aimed at improving robot perception of human movement. - Indian travel‑fintech startup Scapia raised $63 million, with General Catalyst as lead investor. The round also included Peak XV Partners and Z47, and will fund expansion of Scapia’s travel commerce ecosystem and a hiring push for AI talent. - China’s Accro Bioscience secured $50 million in Series C financing from OrbiMed to advance clinical trials for its immune‑mediated disease drug candidate AC‑101. - Forlong Biotechnology obtained roughly $17.5 million in a pre‑Series B round co‑led by Fudan Capital, targeting its cytokine therapy pipeline. - Indonesia’s wealth‑tech platform Pluang attracted $10 million from MUFG Innovation Partners to broaden its multi‑asset offering after launching equities trading. - Hong Kong‑based AEON raised $8 million in a pre‑seed round to build infrastructure for the emerging “agentic economy.” - Additional rounds included Indian robotics firm Anscer ($5.4 M), entertainment‑tech startup Mythik ($5 M), wearable tech company Sychedelic ($3.5 M), trading platform Trackk ($3.16 M), biotech CAR‑T developer Cellogen Therapeutics ($2 M), agri‑finance startup ONO ($1.2 M), digital fashion venture Meta Fashion ($400 K), and QR‑based recovery service Owners ID ($260 K).

What It Means The concentration of large rounds in robotics and fintech underscores a shift toward AI‑enabled hardware and digital financial services. WIRobotics’ sizable Series B suggests confidence in humanoid platforms for industrial and consumer use, while Scapia’s funding highlights the growing intersection of travel and fintech, especially as AI tools become central to product development. Biotech continues to attract substantial capital, but the volume of smaller, early‑stage deals across India and Southeast Asia signals a healthy pipeline of consumer‑focused innovation. Investors appear to be balancing deep‑tech bets with broader market playbooks, creating a diversified funding landscape.

Looking ahead, monitor follow‑on rounds for WIRobotics and Scapia as they scale, and watch for emerging AI‑driven applications in both robotics and fintech that could reshape market dynamics across the region.